Bailard, Inc. Graphite Bio, Inc. Transaction History

Bailard, Inc.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2022 Feb 02, 2023	SELL	$2.82 - $3.59 $43,523 - $55,408	-15,434 Reduced 49.31%	15,866 $52,000
Q3 2022 Oct 18, 2022	BUY	$2.82 - $4.24 $88,266 - $132,712	31,300 New	31,300 $99,000

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.